Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study evaluates the efficacy of dezocine in preventing the catheter-related bladder discomfort (CRBD) in a postanesthesia care unit (PACU).
Thirty min before the end of the surgery, patients were randomly assigned to one of the two group to receive intravenous dezocine 0.1 mg/kg (Group D, n=48) or flurbiprofen axetil 1 mg/kg (Group F, n=48) . The CRBD was assessed at 0, 1, 2, and 6 h after patient's arrival in the post-anaesthesia care unit. Severity of CRBD was graded as none, mild, moderate and severe.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Dezocine | Experimental | 0.1 mg/kg of intravenous dezocine 30 min before the end of surgery |
|
| Flurbiprofen axetil | Active Comparator | 1 mg/kg of intravenous flurbiprofen axetil 30 min before the end of surgery |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dezocine | Drug | Dezocine (0.1 mg/kg）will be infused during surgery |
|
| Measure | Description | Time Frame |
|---|---|---|
| Catheter related bladder discomfort symptoms | CRBD will be evaluated with a 4 point scale (1; no discomfort, 2; mild, revealed on questioning only, 3; moderate, stated by the patient without questioning, 4; severe, urinary urgency executed by behavioral responses, such as attempts to remove urinary catheter, restless extremity movements, verbal responses) | at 1 hour after extubatio |
| Measure | Description | Time Frame |
|---|---|---|
| Catheter related bladder discomfort symptoms | CRBD will be evaluated with a 4 point scale (1; no discomfort, 2; mild, revealed on questioning only, 3; moderate, stated by the patient without questioning, 4; severe, urinary urgency executed by behavioral responses, such as attempts to remove urinary catheter, restless extremity movements, verbal responses) | at 0, 1, 2, and 6 hours after extubation |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jian-jun Yang, PhD | Zhongda Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Zhongda Hospital | Nanjing | Jiangsu | 210009 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C010827 | dezocine |
| C504422 | flurbiprofen axetil |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Flurbiprofen Axetil | Drug | Flurbiprofen Axetil (1 mg/kg）will be infused during surgery |
|
| Severity of pain at suprapubic area | Pain at suprapubic area will be evaluated using VAS after extubation | at 0, 1, 2, and 6 hours after extubation |
| Sedation level | The Ramsay Sedation Scale was measured | at 0, 1, 2, and 6 hours after extubation |
| Incidence of treatment-emergent adverse events | The incidence of nausea, vomiting, hypotension, hypertension, bradycardia,respiratory depression after extubation, and excessive sedation were also recorded | at 0, 1, 2, and 6 hours after extubation |